Jan 10 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O:
4D MOLECULAR THERAPEUTICS INC: PRIMARY ENDPOINT 52-WEEK TOPLINE DATA FOR BOTH 4FRONT-1 AND 4FRONT-2 EXPECTED IN H2 2027
4D MOLECULAR THERAPEUTICS INC: CASH RUNWAY EXTENDED UNDER UPDATED OPERATING PLAN EXPECTED TO FUND OPERATIONS INTO 2028
Source text: nGNX41gQNr
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.